Malta - English - Medicines Authority

mylan pharmaceuticals limited damastown industrial park mulhuddart dublin15 dublin, ireland - piperacillin, tazobactam - powder for solution for infusion - piperacillin 4 g tazobactam 0.5 g - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - piperacillin sodium 2.085 g equivalent to piperacillin 2g; tazobactam sodium 0.2683 g equivalent to tazobactam 0.25g - powder for injection - active: piperacillin sodium 2.085 g equivalent to piperacillin 2g tazobactam sodium 0.2683 g equivalent to tazobactam 0.25g - piperacillin/ tazobactam is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piperacillin/ tazobactam kabi plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piperacillin/tazobactam kabi is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years: in hospitalised children aged 2 to 12 years, piperacillin/ tazobactam is indicated for the treatment of serious intra-abdominal infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - piperacillin sodium 4.17 g equivalent to piperacillin 4g; tazobactam sodium 0.5366 g equivalent to tazobactam 0.5g - powder for injection - active: piperacillin sodium 4.17 g equivalent to piperacillin 4g tazobactam sodium 0.5366 g equivalent to tazobactam 0.5g - piperacillin/ tazobactam is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piperacillin/ tazobactam kabi plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piperacillin/tazobactam kabi is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years: in hospitalised children aged 2 to 12 years, piperacillin/ tazobactam is indicated for the treatment of serious intra-abdominal infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - piperacillin sodium, quantity: 4.253 g; tazobactam sodium, quantity: 0.547 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - pipertaz sandoz is used to treat serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1) lower respiratory tract infections; 2) urinary tract infections (complicated and uncomplicated); 3) intra-abdominal infections; 4) skin and skin structure infections; 5) bacterial septicaemia; 6) gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, pipertaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in children below the age of 2 years. while pipertaz sandoz (piperacillin/tazobactam) is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibility to pipertaz sandoz (piperacillin/tazobactam). therapy with pipertaz sandoz (piperacillin/tazobactam), however, may be initiated before results of each test are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above, however, once these results are available, appropriate therapy should be continued. in serious infections, presumptive therapy with pipertaz sandoz (piperacillin/tazobactam) may be initiated before susceptibility test results are available. combination therapy with pipertaz sandoz (piperacillin/tazobactam) and aminoglycosides may be used int he treatment of serious infections caused by pseudomonas aeruginosa. both drugs shold be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - tazobactam 0.5 g, piperacillin monohydrate 4 g - 0.5 g, 4 g

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - piperacillin sodium ; tazobactam sodium - pdr for soln inj/inf - 2000/250 milligram - piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - piperacillin; tazobactam - powder for solution for infusion - 2 g/0.25 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - piperacillin; tazobactam - powder for solution for infusion - 4 g / 0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - piperacillin sodium; tazobactam sodium - powder for solution for injection/infusion - 2 g/0.25 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - piperacillin sodium; tazobactam sodium - powder for solution for injection/infusion - 4 g/0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor